PMID- 28357672
OWN - NLM
STAT- MEDLINE
DCOM- 20180201
LR  - 20181202
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 1582
DP  - 2017
TI  - Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.
PG  - 197-216
LID - 10.1007/978-1-4939-6872-5_15 [doi]
AB  - Adult T-Cell Leukemia/lymphoma (ATL) is the first human malignancy associated 
      with a chronic infection by a retrovirus, the human T-cell lymphotropic virus 
      type I (HTLV-I). ATL occurs, after a long latency period, only in about 5% of 
      10-20 millions infected individuals. ATL has a dismal prognosis with a median 
      survival of less than 1 year, mainly due to its resistance to chemotherapy and to 
      a profound immunosuppression. The viral oncoprotein, Tax, plays a major role in 
      ATL oncogenic transformation by interfering with cell proliferation, cell cycle, 
      apoptosis, and DNA repair. The diversity in ATL clinical features and prognosis 
      led to Shimoyama classification of ATL into four clinical subtypes (acute, 
      lymphoma, chronic, and smoldering) requiring different therapeutic strategies. 
      Clinical trials, mainly conducted in Japan, demonstrated that combination of 
      chemotherapy could induce acceptable response rate in the lymphoma subtype but 
      not in acute ATL. However, long-term prognosis remains poor for both subtypes, 
      due to a high relapse rate. Similarly, whether managed by a watchful waiting or 
      treated with chemotherapy, the indolent forms (smoldering and chronic) have a 
      poor long-term outcome. An international meta-analysis showed improved survival 
      in the leukemic subtypes of ATL (chronic, smoldering as well as a subset of the 
      acute subtype) with the use of two antiviral agents, zidovudine and 
      interferon-alpha, and accordingly, this combination should be considered the 
      standard first-line treatment in this context. ATL patients with lymphoma subtype 
      benefit from induction chemotherapy, given simultaneously or sequentially with an 
      antiviral combination of zidovudine and interferon-alpha. Allogeneic 
      hematopoietic stem cells transplantation remains a promising and potentially 
      curative approach but is limited to a small number of patients. Novel drugs such 
      as arsenic trioxide in combination with interferon-alpha or monoclonal antibodies 
      such as anti-CXCR4 have shown promising results and warrant further 
      investigation.
FAU - Nasr, Rihab
AU  - Nasr R
AD  - Faculty of Medicine, Department of Anatomy, Cell Biology and Physiology, 
      Americain University of Beirut, 113-6044, Beirut, Lebanon.
FAU - Marcais, Ambroise
AU  - Marcais A
AD  - Department of Hematology, Necker Hospital, University of Paris Descartes, 149, 
      rue de Sevres, Paris, France.
FAU - Hermine, Olivier
AU  - Hermine O
AD  - Department of Hematology, Necker Hospital, University of Paris Descartes, 149, 
      rue de Sevres, Paris, France.
FAU - Bazarbachi, Ali
AU  - Bazarbachi A
AD  - Faculty of Medicine, Department of Anatomy, Cell Biology and Physiology, 
      Americain University of Beirut, 113-6044, Beirut, Lebanon. bazarbac@aub.edu.lb.
AD  - Faculty of Medicine, Department of Internal Medicine, American University of 
      Beirut, 113-6044, Beirut, Lebanon. bazarbac@aub.edu.lb.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Arsenicals)
RN  - 0 (CXCR4 protein, human)
RN  - 0 (Interferon-alpha)
RN  - 0 (Oxides)
RN  - 0 (Receptors, CXCR4)
RN  - 4B9XT59T7S (Zidovudine)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Arsenic Trioxide
MH  - Arsenicals/*therapeutic use
MH  - Female
MH  - *Human T-lymphotropic virus 1
MH  - Humans
MH  - Interferon-alpha/*therapeutic use
MH  - Leukemia-Lymphoma, Adult T-Cell/metabolism/mortality/*therapy
MH  - Male
MH  - Oxides/*therapeutic use
MH  - Receptors, CXCR4/antagonists & inhibitors/metabolism
MH  - Zidovudine/*therapeutic use
OTO - NOTNLM
OT  - ATL
OT  - Antiviral drugs
OT  - Shimoyama classification
OT  - Therapeutic strategies
EDAT- 2017/03/31 06:00
MHDA- 2018/02/02 06:00
CRDT- 2017/03/31 06:00
PHST- 2017/03/31 06:00 [entrez]
PHST- 2017/03/31 06:00 [pubmed]
PHST- 2018/02/02 06:00 [medline]
AID - 10.1007/978-1-4939-6872-5_15 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2017;1582:197-216. doi: 10.1007/978-1-4939-6872-5_15.